Display options
Cite
Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667-77doi: 10.2147/OPTH.S15971.
Chen, J., Runyan, S. A., & Robinson, M. R. (2011). Novel ocular antihypertensive compounds in clinical trials. Clinical ophthalmology (Auckland, N.Z.), 5667-77. https://doi.org/10.2147/OPTH.S15971
Chen, June, et al. "Novel ocular antihypertensive compounds in clinical trials." Clinical ophthalmology (Auckland, N.Z.) vol. 5 (2011): 667-77. doi: https://doi.org/10.2147/OPTH.S15971
Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667-77. doi: 10.2147/OPTH.S15971. Epub 2011 May 20. PMID: 21629573; PMCID: PMC3104796.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2011;5:667-77. doi: 10.2147/OPTH.S15971. Epub 2011 May 20.

Novel ocular antihypertensive compounds in clinical trials.

Clinical ophthalmology (Auckland, N.Z.)

June Chen, Stephen A Runyan, Michael R Robinson

Affiliations

  1. Department of Biological Sciences, Allergan, Inc., 2525 Dupont Dr., Irvine, CA 92612, USA. [email protected]

PMID: 21629573 PMCID: PMC3104796 DOI: 10.2147/OPTH.S15971

Abstract

INTRODUCTION: Glaucoma is a multifactorial disease characterized by progressive optic nerve injury and visual field defects. Elevated intraocular pressure (IOP) is the most widely recognized risk factor for the onset and progression of open-angle glaucoma, and IOP-lowering medications comprise the primary treatment strategy. IOP elevation in glaucoma is associated with diminished or obstructed aqueous humor outflow. Pharmacotherapy reduces IOP by suppressing aqueous inflow and/or increasing aqueous outflow.

PURPOSE: This review focuses on novel non-FDA approved ocular antihypertensive compounds being investigated for IOP reduction in ocular hypertensive and glaucoma patients in active clinical trials within approximately the past 2 years.

METHODS: The mode of IOP reduction, pharmacology, efficacy, and safety of these new agents were assessed. Relevant drug efficacy and safety trials were identified from searches of various scientific literature databases and clinical trial registries. Compounds with no specified drug class, insufficient background information, reformulations, and fixed-combinations of marketed drugs were not considered.

RESULTS: The investigational agents identified comprise those that act on the same targets of established drug classes approved by the FDA (ie, prostaglandin analogs and β-adrenergic blockers) as well as agents belonging to novel drug classes with unique mechanisms of action. Novel targets and compounds evaluated in clinical trials include an actin polymerization inhibitor (ie, latrunculin), Rho-associated protein kinase inhibitors, adenosine receptor analogs, an angiotensin II type 1 receptor antagonist, cannabinoid receptor agonists, and a serotonin receptor antagonist.

CONCLUSION: The clinical value of novel compounds for the treatment of glaucoma will depend ultimately on demonstrating favorable efficacy and benefit-to-risk ratios relative to currently approved prostaglandin analogs and β-blockers and/or having complementary modes of action.

Keywords: antihypertensive; aqueous humor dynamics; clinical trials; drug development; glaucoma progression; intraocular pressure

References

  1. Pharmacol Ther. 2008 Jan;117(1):123-40 - PubMed
  2. J Pharm Sci. 2005 Apr;94(4):701-8 - PubMed
  3. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6461-71 - PubMed
  4. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52 - PubMed
  5. FEBS Lett. 1987 Mar 23;213(2):316-8 - PubMed
  6. Br J Ophthalmol. 2002 Jun;86(6):676-83 - PubMed
  7. Ann Med. 2008;40(6):418-27 - PubMed
  8. Chem Biodivers. 2007 Aug;4(8):1614-48 - PubMed
  9. Arch Ophthalmol. 2003 Jan;121(1):87-90 - PubMed
  10. J Pharmacol Exp Ther. 1993 Oct;267(1):287-95 - PubMed
  11. N Engl J Med. 2009 Mar 12;360(11):1113-24 - PubMed
  12. Curr Opin Cell Biol. 2008 Apr;20(2):242-8 - PubMed
  13. Curr Med Res Opin. 2009 Sep;25(9):2167-77 - PubMed
  14. Biochem Pharmacol. 2010 Sep 15;80(6):846-57 - PubMed
  15. BioDrugs. 2007;21(3):167-77 - PubMed
  16. Nat Rev Mol Cell Biol. 2003 Jun;4(6):446-56 - PubMed
  17. Nature. 2009 Jan 22;457(7228):426-33 - PubMed
  18. Prog Retin Eye Res. 2010 Jul;29(4):284-311 - PubMed
  19. Prog Retin Eye Res. 2005 Sep;24(5):612-37 - PubMed
  20. Exp Eye Res. 2005 May;80(5):629-32 - PubMed
  21. Neuropharmacology. 2008 Nov;55(6):961-8 - PubMed
  22. Acta Ophthalmol. 2010 Feb;88(1):5-11 - PubMed
  23. Pharmacol Rev. 2001 Dec;53(4):527-52 - PubMed
  24. Biochem Biophys Res Commun. 2001 Oct 26;288(2):296-300 - PubMed
  25. Microsc Res Tech. 1999 Oct 1;47(1):18-37 - PubMed
  26. Med Sci Monit. 2010 Nov;16(11):RA252-9 - PubMed
  27. Curr Opin Ophthalmol. 2008 Mar;19(2):85-8 - PubMed
  28. Exp Eye Res. 1997 Jun;64(6):979-89 - PubMed
  29. Exp Eye Res. 2006 Feb;82(2):236-46 - PubMed
  30. Exp Eye Res. 2009 Apr;88(4):760-8 - PubMed
  31. Ophthalmology. 2010 Jul;117(7):1287-93 - PubMed
  32. J Membr Biol. 2003 May 15;193(2):121-36 - PubMed
  33. Br J Pharmacol. 2008 Jan;153(2):390-401 - PubMed
  34. J Pharmacol Exp Ther. 2003 Jul;306(1):301-9 - PubMed
  35. Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1749-58 - PubMed
  36. J Pharmacol Exp Ther. 2007 Jan;320(1):258-65 - PubMed
  37. Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3216-22 - PubMed
  38. Eur J Pharmacol. 2001 Nov 23;431(3):277-86 - PubMed
  39. Curr Eye Res. 2001 Aug;23(2):120-7 - PubMed
  40. Pharmacol Rev. 2006 Sep;58(3):389-462 - PubMed
  41. Exp Cell Res. 2010 May 1;316(8):1284-8 - PubMed
  42. AAPS J. 2010 Dec;12(4):492-503 - PubMed
  43. Arch Ophthalmol. 2008 Mar;126(3):309-15 - PubMed
  44. Exp Eye Res. 2005 May;80(5):697-708 - PubMed
  45. Curr Neuropharmacol. 2008 Dec;6(4):293-310 - PubMed
  46. Nat Rev Drug Discov. 2005 May;4(5):387-98 - PubMed
  47. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1 - PubMed
  48. Optometry. 2010 Jul;81(7):339-50 - PubMed
  49. Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4181-7 - PubMed
  50. Brain Res Bull. 2001 Nov 15;56(5):441-51 - PubMed
  51. Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1497-505 - PubMed
  52. Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254 - PubMed
  53. Cell Signal. 2002 Feb;14(2):99-108 - PubMed
  54. Prog Brain Res. 2008;173:195-210 - PubMed
  55. Ophthalmic Epidemiol. 2006 Aug;13(4):283-9 - PubMed
  56. J Biol Chem. 2006 Jan 6;281(1):260-8 - PubMed
  57. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3775-9 - PubMed
  58. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4042-9 - PubMed
  59. Chem Rev. 2008 May;108(5):1614-41 - PubMed
  60. Nature. 1998 Feb 19;391(6669):806-11 - PubMed
  61. Surv Ophthalmol. 2006 May-Jun;51(3):179-212 - PubMed
  62. Exp Eye Res. 2005 Feb;80(2):197-206 - PubMed
  63. Science. 2009 Nov 27;326(5957):1208-12 - PubMed
  64. Nat Rev Drug Discov. 2006 Mar;5(3):247-64 - PubMed
  65. Exp Eye Res. 2006 Apr;82(4):545-57 - PubMed
  66. Exp Eye Res. 2006 Mar;82(3):362-70 - PubMed
  67. Exp Eye Res. 2009 Apr;88(4):769-75 - PubMed
  68. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4691-6 - PubMed
  69. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3795-9 - PubMed
  70. Exp Eye Res. 2007 Jan;84(1):126-34 - PubMed
  71. Am J Physiol. 1999 Mar;276(3):C659-66 - PubMed
  72. J Cell Sci. 2001 Mar;114(Pt 5):1025-36 - PubMed
  73. Nucleic Acids Res. 2005 Mar 30;33(6):1834-47 - PubMed
  74. Trans Am Ophthalmol Soc. 2004;102:251-7; discussion 257-9 - PubMed
  75. Br J Ophthalmol. 2004 May;88(5):708-13 - PubMed
  76. Exp Eye Res. 2009 Apr;88(4):713-7 - PubMed
  77. Acta Physiol (Oxf). 2006 May-Jun;187(1-2):345-52 - PubMed
  78. Ophthalmology. 2008 May;115(5):790-795.e4 - PubMed
  79. Invest Ophthalmol Vis Sci. 2006 May;47(5):1991-8 - PubMed
  80. Biochem Soc Trans. 2005 Nov;33(Pt 5):891-5 - PubMed
  81. Arch Ophthalmol. 2004 Oct;122(10):1482-8 - PubMed
  82. Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37 - PubMed

Publication Types